Neptune Technologies & Bioressources Environmental Responsibility and Business Conduct Acknowledged by NSF International
09 May 2011 - 10:00PM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) announced that Neptune and its marine
derived products have successfully completed an extensive and
rigorous review of key environmental claims by NSF International.
Neptune has always been committed to providing the best natural
marine-derived products with clinically proven health benefits
while prioritizing environmental responsibility. Sustainability of
krill, the primary biomass used by Neptune, is of paramount
importance for the Company and its existing and potential strategic
partners. The NSF certification will strengthen considerably its
negotiation power and its position in the increasingly demanding
krill industry.
"Neptune committed to a rigorous and transparent audit conducted
by NSF in order for it to verify the environmental impact of
Neptune's process and its products," said Dr. Wael Massrieh, Vice
President, Scientific Affairs. "NSF is an independent, world-wide
recognized not-for-profit organization committed to protecting and
improving public health and the environment," he added.
NSF performed an off-site review of documentation in addition to
an onsite verification of the manufacturing process. The audit was
conducted to ensure clarity and conformance with the strict
criteria of the:
- International Organization for Standardization (ISO) 14021:
Environmental labels and declaration.
- Federal Trade Commission (16 CFR PART 260): Guides for the Use
of Environmental Marketing Claims.
Based on the successful results of this audit and due diligence,
Neptune has been approved by NSF to make the following
environmental claims:
- Neptune only uses krill captured by fisheries that follow the
Antarctic Treaty (1961) rules and respect the annual capture quota
of the Commission for the Conservation of Antarctic Marine Living
Resources (CCAMLR).
- Neptune obtains krill from fisheries that use only mid-water
trawl, which reduces the impact on other species as by-catch.
- Neptune krill oils are alternative sources of marine omega-3
which reduce the pressure on fish populations.
- Neptune's OceanExtractâ„¢ patented process recycles an annual 99%
of the extraction solvent used during the manufacture of Neptune
krill oils.
- Neptune only uses krill that is 100% traceable to the source of
capture.
"The efforts that Neptune put into having their claims verified
is laudable," said Petie Davis, Sustainability Manager at NSF
International. "They demonstrated that they had the systems,
processes, documentation, and data to support all of their product
and process claims," she added.
"This is another significant achievement for Neptune. This NSF
certification will make our partners and consumers aware that our
company Neptune, not only strives to use 100% traceable biomass,
but more importantly is concerned with the sustainability of the
biomass. Neptune is cautious and conscious of the consequences our
actions have on the environment and we act accordingly," said
Sabrina DiBlasio, Marketing Director.
About NSF International NSF International, an
independent, not-for-profit organization certifies products and
writes standards for food, water and consumer goods to minimize
adverse health effects (www.nsf.org). Founded in 1944, NSF is
committed to protecting human health and safety worldwide and
operates in more than 120 countries. NSF is a World Health
Organization Collaborating Centre for Food and Water Safety and
Indoor Environment. NSF International's Sustainability Program
focuses on three areas: product assessment, standards development,
and process verification. NSF International is also a leading
provider of process verification services, which include greenhouse
gas verification, environmental footprinting, and environmental
management systems registrations.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3
phospholipids. Phospholipids are the major component of cell
membranes and are essential for all vital cell processes. They are
one of the principal constituents of High Density Lipoprotein (good
cholesterol) and, as such, play an important role in modulating
cholesterol efflux. Acasti Pharma's proprietary novel phospholipids
carry and functionalize the polyunsaturated omega-3 fatty acids EPA
and DHA, which have been shown to have substantial health benefits
and which are stabilized by potent antioxidants. Acasti Pharma is
focusing initially on treatments for chronic cardiovascular
conditions within the over-the-counter, medical food and
prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Bob Beaty
(888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024